03.13.25 -- How To Build Resilience Amid Dynamic Biopharma Vendor Relationships

With ever increasing speed from DNA to IND, the window for toxicological data generation is becoming shorter and more critical. In this webinar we explore the key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material. Click here to learn more.

Executing or skipping an engineering run is a consequential decision for any biopharma or CDMO and should be supported by all available data as well as a thorough risk assessment.

Medical device companies must meet the demand plan for their devices while managing production costs. Gain valuable insights for scaling up production capabilities efficiently and cost-effectively.

In this presentation, industry-leading bioprocess experts explore the challenges and opportunities that arise when implementing Quality by Design (QbD) in biologics development and manufacturing.

Identifying manufacturing capacity that can adapt to a growing and changing biopharma landscape requires an emphasis on technical and operational expertise combined with agility and flexibility.

By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.

Enable a wide array of genomic manipulation with the more regulated and efficient genomic insertion that's made possible by transposase-based technologies.

Characterizing Fab and Fc-Fusion proteins and developing robust manufacturing processes can help usher them to market and provide new treatment options for diseases that are challenging to treat.

Explore several strategies for selecting the ideal CDMO partner for your pharmaceutical project, helping you navigate the evolving drug development landscape and drive successful outcomes.

This expert Q&A examines ways to push the envelope of expression system technology and process characterization while maximizing user transparency.

Jin-an Jiao, VP of Process and Analytical Development at Synthekine, has worked with CDMOs worldwide. "When starting a new project, everyone seems perfect," he says. "Everybody's great." But that can change fast, highlighting the need to confirm a real commitment to timelines.

Our multi-product manufacturing facilities feature state-of-the-art equipment for animal cell-derived viral and microbial products for your clinical trials in phase 1-2 and in accordance with cGMP guidelines.

With well-equipped, on-site analytical and microbiological laboratories as well as stability chambers, our scientists monitor end-to-end processes to confirm the safety and quality of each batch.

United by a passion for innovation, our global team delivers life-changing products with expertise and process excellence, partnering with top pharmaceutical companies worldwide.

We offer a comprehensive suite of bioanalytical and spatial biology solutions designed to support the progression of your molecule from discovery through clinical development and product approval.